免疫检查点抑制剂治疗上尿路与下尿路晚期尿路上皮癌的结局比较
这项多中心回顾性队列研究纳入2013至2020年接受免疫检查点抑制剂治疗的晚期尿路上皮癌患者,比较上尿路与下尿路患者的客观缓解率、总生存期和无进展生存期。结果显示两组总体疗效和结局相当,但混合组织学上尿路癌患者的客观缓解率更低且无进展生存期更短。
要点
- 上尿路与下尿路晚期尿路上皮癌接受免疫检查点抑制剂的总体疗效和生存结局相当。
- 混合组织学上尿路癌患者的客观缓解率显著低于混合组织学下尿路癌。
- 混合组织学上尿路癌患者的无进展生存期显著短于混合组织学下尿路癌。
核心结论
- 总体上,接受免疫检查点抑制剂治疗的上尿路与下尿路晚期尿路上皮癌患者具有可比的治疗反应和结局。
- 基于组织学的亚组分析显示,混合组织学上尿路癌较混合组织学下尿路癌的客观缓解率更低且无进展生存期更短。
研究设计与样本
- 多中心回顾性队列研究,收集2013至2020年24家机构中接受免疫检查点抑制剂治疗的晚期尿路上皮癌患者的临床病理、治疗和结局数据。
- 共746例符合条件患者,分别有707例、717例和738例纳入客观缓解率、总生存期和无进展生存期分析。
主要发现
- 上尿路与下尿路患者的客观缓解率分别为24%和28%(调整比值比0.73,95%置信区间0.43-1.24)。
- 上尿路与下尿路患者的中位总生存期分别为9.8个月和9.6个月(调整风险比0.93,95%置信区间0.73-1.19)。
- 上尿路与下尿路患者的中位无进展生存期分别为4.3个月和4.1个月(调整风险比1.01,95%置信区间0.81-1.27)。
- 混合组织学上尿路癌较混合组织学下尿路癌的客观缓解率调整比值比为0.20(95%置信区间0.05-0.91),无进展生存期调整风险比为1.66(95%置信区间1.06-2.59)。
临床怎么用
- 对于晚期上尿路与下尿路尿路上皮癌,免疫检查点抑制剂治疗可考虑作为可比的系统治疗选择。
- 混合组织学上尿路癌患者接受免疫检查点抑制剂时可能需要更密切的疗效监测和个体化评估。
局限性
- 本研究为回顾性队列研究,可能存在选择偏倚和未测量的混杂因素。
- 亚组分析基于组织学和治疗线数分层,样本量可能有限,结果需进一步验证。
- 需要进一步研究和分子生物标志物评估以优化免疫治疗的 patient selection。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). PATIENTS AND METHODS: We performed a retrospective cohort study collecting clinicopathological, treatment, and outcome data for patients with aUC receiving ICIs from 2013 to 2020 across 24 institutions. We compared the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) between patients with upper and lower tract UC (UTUC, LTUC). Uni- and multivariable logistic and Cox regression were used to assess the effect of UTUC on ORR, OS, and PFS. Subgroup analyses were performed stratified based on histology (pure, mixed) and line of treatment (first line, subsequent line). RESULTS: Out of a total of 746 eligible patients, 707, 717, and 738 were included in the ORR, OS, and PFS analyses, respectively. Our results did not contradict the hypothesis that patients with UTUC and LTUC had similar ORRs (24% vs 28%; adjusted odds ratio [aOR] 0.73, 95% confidence interval [CI] 0.43-1.24), OS (median 9.8 vs 9.6 months; adjusted hazard ratio [aHR] 0.93, 95% CI 0.73-1.19), and PFS (median 4.3 vs 4.1 months; aHR 1.01, 95% CI 0.81-1.27). Patients with mixed-histology UTUC had a significantly lower ORR and shorter PFS vs mixed-histology LTUC (aOR 0.20, 95% CI 0.05-0.91 and aHR 1.66, 95% CI 1.06-2.59), respectively). CONCLUSION: Overall, patients with UTUC and LTUC receiving ICIs have comparable treatment response and outcomes. Subgroup analyses based on histology showed that those with mixed-histology UTUC had a lower ORR and shorter PFS compared to mixed-histology LTUC. Further studies and evaluation of molecular biomarkers can help refine patient selection for immunotherapy.
引用
- Esagian SM, Khaki AR, Diamantopoulos LN, et al. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int. 2021. PMID: 33556233. doi:10.1111/bju.15324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。